Key result
Catheter-directed thrombolysis yielded higher iliofemoral vein patency at 6 months (69.2% vs 38.5%, p=0.05) and lower post-thrombotic syndrome at 12 months (19.2% vs 50%, p=0.04) than enoxaparin.
Why the study?
Does catheter-directed thrombolysis improve vein patency and reduce post-thrombotic syndrome compared to enoxaparin in patients with acute proximal deep vein thrombosis?
Population
53 patients with acute proximal deep vein thrombosis (DVT)
Comparison
Catheter-directed thrombolysis followed by… vs Adjusted subcutaneous low-molecular-weight…
Design
Cohort
Follow-up
mean 15.2 months
Authors
Loading...
Should not change practice for proximal DVT; leaves open need for randomized confirmation of observational benefits.
Cohort (n=53)
Does catheter-directed thrombolysis improve vein patency and reduce post-thrombotic syndrome compared to enoxaparin in patients with acute proximal deep vein thrombosis?
Absolute Event Rate: 69.2% vs 38.5%
p-value: p=0.05
Catheter-directed thrombolysis for acute proximal DVT is associated with higher early vein recanalization and a lower incidence of post-thrombotic syndrome at 12 months compared to standard anticoagulation.
Lee et al. (2013) conducted a cohort in acute proximal deep vein thrombosis (n=53). catheter-directed intrathrombus thrombolysis (CDT) vs. enoxaparin (low-molecular-weight heparin) was evaluated on patency of the iliofemoral vein segment after 6 months (p=0.05). Catheter-directed thrombolysis yielded higher iliofemoral vein patency at 6 months (69.2% vs 38.5%, p=0.05) and lower post-thrombotic syndrome at 12 months (19.2% vs 50%, p=0.04) than enoxaparin.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: